Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study
Article in Signal Transduction and Targeted Therapy (May 2024)
The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.
Article in Signal Transduction and Targeted Therapy (May 2024)
Article in Cancer Medicine (March 2023)
Article in Translational Oncology (April 2022)